These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 28232731)

  • 1. Roles of Serum Calcium, Phosphorus, PTH and ALP on Mortality in Peritoneal Dialysis Patients: A Nationwide, Population-based Longitudinal Study Using TWRDS 2005-2012.
    Liu CT; Lin YC; Lin YC; Kao CC; Chen HH; Hsu CC; Wu MS
    Sci Rep; 2017 Feb; 7(1):33. PubMed ID: 28232731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. International variations in serum PTH and calcium levels and their mortality associations in peritoneal dialysis patients: Results from PDOPPS.
    Nitta K; Bieber B; Karaboyas A; Johnson DW; Kanjanabuch T; Kim YL; Lambie M; Hartman J; Shen JI; Naljayan M; Pecoits-Filho R; Robinson BM; Pisoni RL; Perl J; Kawanishi H
    Perit Dial Int; 2024 Jul; 44(4):275-286. PubMed ID: 38501163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative mortality-predictability using alkaline phosphatase and parathyroid hormone in patients on peritoneal dialysis and hemodialysis.
    Rhee CM; Molnar MZ; Lau WL; Ravel V; Kovesdy CP; Mehrotra R; Kalantar-Zadeh K
    Perit Dial Int; 2014; 34(7):732-48. PubMed ID: 24385335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High alkaline phosphatase and low intact parathyroid hormone associate with worse clinical outcome in peritoneal dialysis patients.
    Chen Z; Zhang X; Han F; Xie X; Hua Z; Huang X; Lindholm B; Haarhaus M; Stenvinkel P; Qureshi AR; Chen J
    Perit Dial Int; 2021 Mar; 41(2):236-243. PubMed ID: 32363998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in Markers of Mineral and Bone Disorders and Mortality in Incident Hemodialysis Patients.
    Soohoo M; Feng M; Obi Y; Streja E; Rhee CM; Lau WL; Wang J; Ravel VA; Brunelli S; Kovesdy CP; Kalantar-Zadeh K
    Am J Nephrol; 2016; 43(2):85-96. PubMed ID: 26950688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvement of mineral and bone metabolism markers is associated with better survival in haemodialysis patients: the COSMOS study.
    Fernández-Martín JL; Martínez-Camblor P; Dionisi MP; Floege J; Ketteler M; London G; Locatelli F; Gorriz JL; Rutkowski B; Ferreira A; Bos WJ; Covic A; Rodríguez-García M; Sánchez JE; Rodríguez-Puyol D; Cannata-Andia JB;
    Nephrol Dial Transplant; 2015 Sep; 30(9):1542-51. PubMed ID: 25920921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Parameters of Mineral Bone Disorder with Mortality in Patients on Hemodialysis according to Level of Residual Kidney Function.
    Wang M; Obi Y; Streja E; Rhee CM; Lau WL; Chen J; Hao C; Hamano T; Kovesdy CP; Kalantar-Zadeh K
    Clin J Am Soc Nephrol; 2017 Jul; 12(7):1118-1127. PubMed ID: 28487345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Drug Effects on Serum Parathyroid Hormone, Phosphorus, and Calcium Levels With Mortality in CKD: A Meta-analysis.
    Palmer SC; Teixeira-Pinto A; Saglimbene V; Craig JC; Macaskill P; Tonelli M; de Berardis G; Ruospo M; Strippoli GF
    Am J Kidney Dis; 2015 Dec; 66(6):962-71. PubMed ID: 26003472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal targets of chronic kidney disease-mineral and bone disorder markers for Chinese patients with maintenance peritoneal dialysis: a single-center retrospective cohort study.
    Chen L; Tang X; Zheng H; Wang H; Xia P; Wang Y; Zhao X; Zhou Z; Qiu L; Li X
    Ren Fail; 2022 Dec; 44(1):336-345. PubMed ID: 35380083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detecting high-risk chronic kidney disease-mineral bone disorder phenotypes among patients on dialysis: a historical cohort study.
    Neri L; Kreuzberg U; Bellocchio F; Brancaccio D; Barbieri C; Canaud B; Stuard S; Ketteler M
    Nephrol Dial Transplant; 2019 Apr; 34(4):682-691. PubMed ID: 30165528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aberrant serum parathyroid hormone, calcium, and phosphorus as risk factors for peritonitis in peritoneal dialysis patients.
    Liao CT; Zheng CM; Lin YC; Wu MY; Lin YF; Hsu YH; Hsu CC; Wu MS
    Sci Rep; 2021 Jan; 11(1):1171. PubMed ID: 33441921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Kidney Disease Outcomes Quality Initiative (K/DOQI) Guideline for Bone Metabolism and Disease in CKD: association with mortality in dialysis patients.
    Noordzij M; Korevaar JC; Boeschoten EW; Dekker FW; Bos WJ; Krediet RT;
    Am J Kidney Dis; 2005 Nov; 46(5):925-32. PubMed ID: 16253734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of chronic kidney disease-mineral and bone disorder in incident peritoneal dialysis patients and its association with short-term outcomes.
    Chuang SH; Wong HC; Vathsala A; Lee E; How PP
    Singapore Med J; 2016 Nov; 57(11):603-609. PubMed ID: 26778726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect Modifying Role of Serum Calcium on Mortality-Predictability of PTH and Alkaline Phosphatase in Hemodialysis Patients: An Investigation Using Data from the Taiwan Renal Registry Data System from 2005 to 2012.
    Lin YC; Lin YC; Hsu CY; Kao CC; Chang FC; Chen TW; Chen HH; Hsu CC; Wu MS;
    PLoS One; 2015; 10(6):e0129737. PubMed ID: 26107510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal study on the change trend of serum alkaline phosphatase and its possible influencing factors in peritoneal dialysis patients.
    Zhao W; Zhang S; Zhao HD
    Sci Rep; 2024 Jun; 14(1):13099. PubMed ID: 38849443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adherence to Kidney Disease: Improving Global Outcomes Mineral and Bone Guidelines for Monitoring Biochemical Parameters.
    Roetker NS; Peng Y; Ashfaq A; Gilbertson DT; Wetmore JB
    Am J Nephrol; 2019; 49(3):225-232. PubMed ID: 30820015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome predictability of serum alkaline phosphatase in men with pre-dialysis CKD.
    Kovesdy CP; Ureche V; Lu JL; Kalantar-Zadeh K
    Nephrol Dial Transplant; 2010 Sep; 25(9):3003-11. PubMed ID: 20299338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of CKD-MBD in pre-dialysis patients using biochemical markers in Enugu, South-East Nigeria.
    Okoye JU; Arodiwe EB; Ulasi II; Ijoma CK; Onodugo OD
    Afr Health Sci; 2015 Sep; 15(3):941-8. PubMed ID: 26957985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High prevalence of biochemical disturbances of chronic kidney disease - mineral and bone disorders (CKD-MBD) in a nation-wide peritoneal dialysis cohort: are guideline goals too hard to achieve?
    Weissheimer R; Bucharles SGE; Truyts CAM; Jorgetti V; Figueiredo AE; Barrett P; Olandoski M; Pecoits-Filho R; Moraes TP
    J Bras Nefrol; 2021; 43(2):173-181. PubMed ID: 33538758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS).
    Tentori F; Blayney MJ; Albert JM; Gillespie BW; Kerr PG; Bommer J; Young EW; Akizawa T; Akiba T; Pisoni RL; Robinson BM; Port FK
    Am J Kidney Dis; 2008 Sep; 52(3):519-30. PubMed ID: 18514987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.